- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Ocriplasmin BLA granted priority review
ThromboGenics NV has announced that the FDA has accepted the filing of the biologics license application (BLA) for ocriplasmin intravitreal injection 2.5 mg/ml and granted it priority review. The proposed indication of ocriplasmin intravitreal injection is for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole.
Leuven, Belgium-ThromboGenics NV has announced that the FDA has accepted the filing of the biologics license application (BLA) for ocriplasmin intravitreal injection 2.5 mg/ml and granted it priority review. The proposed indication of ocriplasmin intravitreal injection is for the treatment of symptomatic vitreomacular adhesion (VMA) including macular hole.
The FDA has scheduled an advisory committee meeting on July 26 to discuss the ocriplasmin BLA and has assigned the ocriplasmin BLA a prescription drug user fee act goal date of Oct. 17.
Ocriplasmin has successfully completed two phase III clinical trials for the pharmacologic treatment of symptomatic VMA, including that associated with macular hole. The marketing authorization application for ocriplasmin has been accepted for review in Europe.
For more articles in this issue of Ophthalmology Times eReport, click here.
